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The Journal of Immunology
Suppression of IRAK1 or IRAK4 Catalytic Activity, but Not
Type 1 IFN Signaling, Prevents Lupus Nephritis in Mice
Expressing a Ubiquitin Binding–Defective Mutant of ABIN1
Sambit K. Nanda,*,1 Marta Lopez-Pelaez,*,1,2 J. Simon C. Arthur,† Francesco Marchesi,‡
and Philip Cohen*
Polymorphisms in the TNIP1 gene encoding A20-binding inhibitor of NF-kB1 (ABIN1) predispose to lupus and other autoimmune
diseases in at least eight human populations. We found previously that knock-in mice expressing a ubiquitin-binding–defective
mutant of ABIN1 (ABIN1[D485N]) develop autoimmunity as they age and succumb to a disease resembling lupus nephritis in
humans. In this article, we report that Flt3-derived dendritic cells from these mice overproduced type 1 IFNs upon stimulation
with ligands that activate TLR7 or TLR9. However, crossing ABIN1[D485N] mice to IFNAR1-knockout mice that do not express
the a-subunit of the type 1 IFNR did not prevent splenomegaly, the appearance of high serum levels of autoantibodies and other
Igs, or liver inflammation and only reduced kidney inflammation modestly. In contrast, crossing ABIN1[D485N] mice to knock-in
mice expressing catalytically inactive mutants of IRAK1 or IRAK4 prevented splenomegaly, autoimmunity, and liver and kidney
inflammation. Our results support the notion that IRAK1 and/or IRAK4 are attractive targets for the development of drugs to
prevent, and perhaps treat, lupus nephritis and other autoinflammatory diseases caused by the decreased ability of ABIN1 or
other proteins to restrict the strength of MyD88 signaling. The Journal of Immunology, 2016, 197: 4266–4273.
T
he protein A20-binding inhibitor of NF-kB1 (ABIN1) is
required to prevent systemic lupus erythematosus (SLE),
because mutant mice expressing the functionally defec-
tive ABIN1[D485N] mutant, which cannot interact with ubiquitin
chains, leads to the spontaneous development of autoimmunity
(1). ABIN1[D485N] mice develop splenomegaly several months
after birth. Their spleens contain far more germinal centers than
those of wild-type (WT) mice, leading to elevated levels of Igs in
the serum after 5–6 mo, which include Igs to host nuclear Ags and
dsDNA. Immune complexes are deposited on the kidneys and on
the blood vessels of the spleen and heart, leading to the recruit-
ment of complement factors and severe inflammation and destruction
of these organs (1). A similar phenotype was observed in ABIN1-
knockout (KO) mice (2). Renal disease that develops spontaneously in
ABIN1[D485N] mice is characterized by focal-to-diffuse proliferative
glomerulonephritis resembling the class III and IV lupus nephritis
observed in human SLE patients (3). Moreover, genome-wide asso-
ciation studies identified polymorphisms in TNIP1, the gene encoding
ABIN1, which predispose to lupus, psoriasis, and other autoimmune
disorders in eight human populations (4–13). Two polymorphisms
were associated with reduced expression of ABIN1 protein (13).
These findings, and the increased severity of the disease observed in
female animals (1), suggest that the ABIN1[D485N]–knock-in mouse
may be a good model for some forms of human lupus.
Enhanced expression of IFN-regulated genes, termed the IFN
signature (14–17), was observed in a number of human patients with
SLE, and Abs that neutralize IFN-a isotypes have entered clinical
trials (18, 19). In this study, we found that the production of type 1
IFNs by plasmacytoid dendritic cells (pDCs) from ABIN1[D485N]
mice was enhanced. This led us to cross them to IFNAR1-KO mice,
a receptor essential for all known type 1 IFN signaling events. How-
ever, we found that crossing ABIN1[D485N] mice to IFNAR1-KO
mice did not suppress the development of autoimmunity and only
modestly reduced kidney inflammation. Therefore, we explored other
possible ways in which autoimmunity might be prevented.
We showed previously that autoimmunity inABIN1[D485N]mice is
prevented by crossing them to MyD88-KO mice, establishing that
hyperactivation of the MyD88 signaling network underlies the disease
(1). In this pathway, the activation of TLRs recruits the adaptor
molecule MyD88, which is followed by interaction of MyD88 with
IRAK4 and then the interaction of IRAK4 with other IRAK family
members to form an oligomeric complex termed the Myddosome (20,
21). Myddosome formation induces the formation of hybrid ubiquitin
chains containing Lys63-linked and Met1-linked ubiquitin oligomers
(22), which facilitate activation of the canonical IkB kinase (IKK)
complex by the protein kinase TGF-b–activated kinase 1 (TAK1) (22,
23, reviewed in Ref. 24). The IKK complex activates the two critical
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transcription factors NF-kB and IRF5 (25, 26), whereas TAK1 also
induces activation of the JNKs and p38 MAPKs, which switch on
additional transcription factors and stimulate posttranscrip-
tional events controlling the synthesis, processing, and secretion of
inflammatory mediators. ABIN1 interacts with Lys63- and Met1
-linked ubiquitin oligomers and is thought to compete with the TAK1
and IKK complexes for binding to the hybrid ubiquitin chains formed
when this signaling pathway is activated. This explains why TAK1
and IKK are hyperactivated and the secretion of proinflammatory
cytokines, such as IL-6, IL-12, and TNF-a, is enhanced in dendritic
cells (DCs) expressing the ubiquitin-binding–defective ABIN1
[D485N] mutant (1). These findings suggested that ABIN1[D485N]
mice could be used to identify components of the MyD88 signaling
pathway that might be attractive targets for the development of drugs
to prevent and treat lupus. Therefore, we also crossed ABIN1
[D485N] mice to mice expressing catalytically inactive mutants of
IRAK1 (27) or IRAK4, as well as a functionally defective mutant of
IRAK2 (28), the results of which are also reported in this article.
Materials and Methods
Generation and maintenance of mouse lines
ABIN1[D485N]–knock-in (1), IRAK2[E525A]–knock-in (28), and IRAK1
[D359A]–knock-in (27) mice were described. ABIN1[D485N] mice were
back-crossed to C57BL6/J mice (Jackson Laboratory) for up to 10 gen-
erations, IRAK1[D359A] mice up to 10 generations, and IRAK2[D525A]
mice up to 8 generations. IRAK4[D329A]–knock-in mice were developed
by Taconic-Artemis using embryonic stem cells from C57BL/6 mice and
were further back-crossed to C57BL6/J mice for six generations. The
C57BL/6 strain from Jackson Laboratory that was used for backcrossing
these mice is free of the DOCK2 mutation that is reported to be present in
C57BL mice from Harlan Laboratories and that affects the immune system
(29). IFNAR1-KO mice (Crick Institute, London, U.K.) (30) were on a
C57BL/6 background and were further backcrossed to C57BL6/J mice for
six generations. Mice were maintained in individually ventilated cages
under specific pathogen–free conditions, given free access to food and
water, and housed in accordance with U.K. and European Union regula-
tions. All procedures were carried out under a U.K. Home Office Project
License and were subjected to local ethical review.
TLR agonists
The TLR agonists Pam3CSK4 (TLR1/2), R848 (TLR7), CpG type A
(ODN1585) (TLR9), and CpG type B (ODN1826) (TLR9) were from
InvivoGen, and poly(dU) (TLR7) was from Sigma-Aldrich. Poly(dU) was
added to the culture medium conjugated with Lipofectamine 2000 (Invi-
trogen), as described (28).
Characterization of Flt3-derived DCs
The percentage of pDCs in Flt3-derived cell populations was assessed by
staining with B220, PDCA1, CD11c, and CD11b Abs (Becton-Dickinson)
and analyzed by flow cytometry.
Abs
Abs recognizing p105/NFkB1 phosphorylated at Ser933, p38a MAPK phos-
phorylated at its Thr-Gly-Tyr motif, total p38a MAPK, total IRAK4, and
GAPDH were from Cell Signaling Technology. An Ab recognizing IRAK4
phosphorylated at Thr345 and Ser346 was provided by V. Rao (Pfizer) (31). An
FIGURE 1. Enhanced IFN secretion in Flt3-
derived DCs from ABIN1[D485N] mice. Flt3-
derived DCs (3.53 105 cells) from 6–8-wk-old
WT mice or ABIN1[D485N] mice were stim-
ulated for 12 h with the indicated concentra-
tions of poly(dU) (A and D), CpG A (B and E),
or CpG B (C and F). The concentrations of
IFN-b (A–C) and IFN-a (D–F) in the cell cul-
ture medium was measured by ELISA using
a mouse IFN-b kit (BioLegend) or VeriKine
Mouse IFN Alpha ELISA Kit (PBL IFN
Source), respectively. Error bars represent the
mean 6 SEM for four separate experiments
carried out on cells from a total of 12 mice
for each genotype. *p # 0.05, **p # 0.01,
****p # 0.0001, Student t test.
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Ab recognizing JNKs phosphorylated at their Thr-Pro-Tyr motif was from
Invitrogen, and a rabbit secondary Ab conjugated to HRP was from Pierce.
Histopathological analysis
Mice were euthanized by increasing CO2 levels. The kidneys and liver from
each mouse were removed, fixed in 10% neutral buffered formalin for $48
h, and then embedded in paraffin. For liver, one sample from the left lobe
and two from the median lobe were trimmed and processed. Sections
(4 mm) were prepared, and liver and kidney sections were stained with
H&E. Kidney sections were also stained with periodic acid–Schiff (PAS)
reagent, and liver sections were stained with Sirius Red. Kidney and liver
tissue sections were assessed by a veterinary pathologist (F.M.) who was
blinded to the genotype of the mice in the different cohorts. The multi-
parametric semiquantitative scoring system used to assess renal and liver
changes was based on the principles and guidelines for histopathologic
scoring in research (32).
FIGURE 2. Enhanced ifn-b and ifn-a mRNA in Flt3-
derived DCs from ABIN1[D485N] mice. Flt3-derived
DCs (3.5 3 105 cells) from 6–8-wk-old WT mice or
ABIN1[D485N] mice were stimulated for 12 h with the
indicated concentrations of poly(dU) (A and D), CpG A
(B and E), or CpG B (C and F). The total RNA was
extracted from the cells, and mRNA encoding ifn-b
(A–C) or ifna4 (D–F) was measured by quantitative
RT-PCR. Error bars represent the mean6 SEM for four
separate experiments carried out on cells from a total
of 12 mice for each genotype. *p # 0.05, **p # 0.01,
***p # 0.001, ****p # 0.0001, Student t test.
FIGURE 3. Hallmarks of autoimmunity are not reduced
in ABIN1[D485N] 3 IFNAR1-KO mice. Three WT mice,
six or seven ABIN1[D485N] mice, six or seven ABIN1
[D485N] 3 IFNAR1-KO mice, and four IFNAR1-KO mice
were used for all of the experiments. (A) Spleen weights of
6-mo-old WT mice (s), ABIN1[D485N]–knock-in mice
(N), ABIN1[D485N] 3 IFNAR1-KO mice (O), and
IFNAR1-KO mice ()). Each symbol represents data from
one mouse, and the horizontal lines show the average 6
SEM. Total ANAs (B), anti-dsDNA Abs (C), and Ig isotypes
(D) in the serum of 6-mo-old mice of the indicated geno-
types were measured by ELISA. Each symbol represents
one mouse, and the horizontal lines shows the average 6
SEM. *p , 0.05, Mann–Whitney U test. ns, not significant.
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Other methods
Generation and culture of bone marrow–derived macrophages (BMDMs)
and Flt3-derived DCs, cell lysis, immunoblotting and cytokine measure-
ments, cDNA synthesis, and RNA extraction were carried out as described
(28). Quantitative PCR was performed as described (28), with the excep-
tion that SsoFast EvaGreen Supermix (Bio-Rad) was used. The primers
used to measure ifnb, ifna4, and ifna6 mRNA were described previously
(33). Autoantibodies were measured by ELISA (1), and Ig isotypes were
measured using a kit from Millipore.
Statistical significance
Statistical significance was calculated using the two-tailed Student t test or
Mann–Whitney U test with GraphPad Prism software. Additional details
are given in the figure legends.
Results
Type 1 IFNs are overproduced in Flt3-derived DCs from
ABIN1[D485N] mice
pDCs are a major source of the type 1 IFNs produced by theMyD88
signaling network. Therefore, we compared IFN production in
Flt3-derived DCs from ABIN1[D485N] and WT mice, which are
widely used as a model for pDC function (34). We found that Flt3-
derived DCs from ABIN1[D485N] mice secreted much higher
levels of IFN-b (Fig. 1A–C) and IFN-a (Fig. 1D–F) and produced
much higher levels of ifnb (Fig. 2A–C), ifna4 (Fig. 2D–F) and
ifna6 mRNA (Supplemental Fig. 2) than pDCs from WT mice
(note that the ordinates in Fig. 2 and Supplemental Fig. 2 are plotted
on a log scale). Enhanced type 1 IFN production was not explained
by an increased proportion of B220+ and PDCA+ pDCs in the
preparations from ABIN1[D485N] mice. Indeed, the proportion of
these cells relative to B2202 and PDCA2 cells was lower in prep-
arations from these mice (27.76 6 2.02% versus 37.18 6 2.77% in
WT mice). In contrast, the proportion of B2202 and PDCA2 cells
increased from 4.8 6 0.73% in WT mice to 6.1 6 1.0% in ABIN1
[D485N] mice. Taken together, our results demonstrate that ABIN1
restricts the production of type 1 IFNs in Flt3-derived DCs.
Lupus nephritis in ABIN1[D485N] 3 IFNAR1-KO mice
These experiments raised the question of whether the elevated levels
of type 1 IFNs in ABIN[D485N] mice were responsible for the
development of lupus nephritis in these animals. Therefore, we
crossed them to IFNAR1-KO mice, a gene essential for every known
signaling event triggered by type 1 IFNs. At 6 mo of age, ABIN1
[D485N] 3 IFNAR1-KO mice showed enlarged spleens that were
similar in size to those observed in ABIN1[D485N] mice (Fig. 3A),
and the high serum levels of anti-nuclear Abs (ANAs), anti-self
dsDNA, or other Ig isotypes in ABIN1[D485N] mice were not
reduced in ABIN1[D485N] 3 IFNAR1-KO mice (Fig. 3B–D). In
contrast, there was a partial reduction in the extent of glomerulo-
nephritis in ABIN1[D485N] 3 IFNAR1-KO mice compared with
ABIN1[D485N] mice (Fig. 4A, 4C). However, the liver inflam-
mation found in ABIN1[D485N] mice at 6 mo of age was not re-
duced in ABIN1[D485N] 3 IFNAR1-KO mice (Fig. 4B, 4D).
Lupus nephritis and liver inflammation in ABIN1[D485N] mice
are prevented by crossing to mice expressing catalytically
inactive mutants of IRAK1 or IRAK4
We showed previously that autoimmunity in ABIN1[D485N] mice
is prevented by crossing to MyD88-KOmice (1). Because the other
FIGURE 4. Reduced glomerulonephritis but unaf-
fected liver inflammation in ABIN1[D485N] 3 IFNAR1-
KO mice. Representative H&E staining of kidney (A) and
liver (B) sections from 6-mo-old WT mice, ABIN1
[D485N]–knock-in mice, ABIN1[D485N] 3 IFNAR1-
KO mice, and IFNAR1-KO mice. Scale bars, 0.05 mm.
Assessment of kidney (C) and liver (D) pathology scores
(see Materials and Methods) from two WT mice, seven
ABIN1[D485N] mice, six ABIN1[D485N 3 IFNAR1-
KO mice, and four IFNAR1-KO mice. *p, 0.05, Mann–
Whitney U test.
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components of the Myddosome are IRAK1 and IRAK4 and the
inactive pseudokinase IRAK2, we studied whether the loss of
IRAK1 or IRAK4 catalytic activity, or IRAK2 function, prevented
lupus in ABIN1[D485N] mice.
To investigate the importance of IRAK4 catalytic activity, we
generated a knock-in mouse in which IRAK4 was replaced by the
kinase-inactive IRAK4[D329A] mutant (Supplemental Fig. 1).
This mutation prevents interaction of Asp329 with the magnesium
ion of Mg-ATP without significantly affecting kinase conforma-
tion (35). Similar to mice expressing different kinase-inactive
IRAK4 mutants (36, 37), IFN-b or IFN-a secretion induced by
TLR ligation was undetectable in Flt3-derived DCs from IRAK4
[D329A] mice (Supplemental Fig. 3A, 3B), and TNF-a, IL-6, and
IL-12p40 secretion (Supplemental Fig. 3C–E) and MyD88 sig-
naling (Fig. 3F, 3G) in BMDMs were also greatly reduced. IRAK4
[D329A] mice, as well as the kinase-inactive IRAK1[D359A]
mice (27), were then crossed to ABIN1[D485N] mice.
Neither ABIN1[D485N] 3 IRAK4[D329A] mice nor ABIN1
[D485N] 3 IRAK1[D359A] mice developed splenomegaly
(Fig. 5A) and, consistent with these observations, the levels of
ANAs (Fig. 5B), dsDNA Abs (Fig. 5C), and other IgGs and IgM
(Fig. 5D) in the serum of these mice were similar to WT mice.
However, the high level of IgA found in the serum of ABIN1
[D485N] mice was suppressed by crossing to IRAK4[D329A] mice
but not by crossing to IRAK1[D359A] mice (Fig. 5D). Moreover,
no kidney inflammation was detectable in ABIN1[D485N] 3
IRAK4[D329A] mice or ABIN1[D485N] 3 IRAK1[D359A] mice
at 6 mo of age (Fig. 6) (see Materials and Methods for scoring
system), and the liver inflammation present in ABIN1[D485N]–
knock-in mice was also largely reduced after crossing to IRAK4
[D329A] or IRAK1[D359A] mice (Fig. 7B). Liver fibrosis along
with inflammatory changes observed in ABIN1[D485N] mice were
drastically reduced after crossing to IRAK4[D329A] or IRAK1
[D359A] mice but were not reduced by crossing to IFNAR1-KO
mice (Supplemental Fig. 4).
We also crossed ABIN1[D485N] mice to knock-in mice
expressing the IRAK2[E525A] mutant, which is unable to interact
with TRAF6. Proinflammatory cytokine production induced by
several TLR agonists is greatly reduced in BMDMs from IRAK2
[E525A]–knock-in mice (28). ABIN1[D485N] 3 IRAK2[E525A]
mice still displayed splenomegaly and increased levels of auto-
antibodies and other Igs at 6 mo of age, similar to ABIN1[D485N]
mice (Fig. 5). Moreover, the extent of kidney inflammation in
ABIN1[D485N] 3 IRAK2[E525A] mice was similar to that in
FIGURE 5. Autoimmunity in ABIN1[D485N] mice is prevented by crossing to mice expressing kinase-inactive mutants of IRAK4 or IRAK1. A total of
9 or 10 WT mice, 10 ABIN1[D485N] mice, 10 ABIN1[D485N]3 IRAK4[D329A] mice, 8 ABIN1[D485N] 3 IRAK1[D359A] mice, 6 ABIN1[D485N] 3
IRAK2[E525A] mice, 7 or 8 IRAK4[D329A] mice, 7 or 8 IRAK1[D359A] mice, and 5 IRAK2[E525A] mice were used for all the experiments. (A) Spleen
weights of 6-mo-old mice of the indicated genotypes. Each symbol represents one mouse, and the horizontal lines show the average 6 SEM. Total ANAs
(B), anti-dsDNA Abs (C), and Ig isotypes (D) in the serum of 24-wk-old mice of the indicated genotypes were measured by ELISA. (B and C) Each symbol
represents one mouse, and the horizontal lines shows the average 6 SEM. **p . 0.005, ***p , 0.005, Mann–Whitney U test. ns, nonsignificant.
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ABIN1[D485N] mice (Fig. 6). Interestingly, liver inflammation
and attending fibrosis were partially reduced in ABIN1[D485N]3
IRAK2[E525A] mice (Fig. 7, Supplemental Fig. 4).
Discussion
Type 1 IFNs, which have important roles in regulating innate and
adaptive immunity, also were implicated in the pathogenesis of
lupus. However, we report that, although crossing ABIN1[D485N]
mice to IFNAR1-KO mice modestly reduced kidney inflamma-
tion, it did not prevent the splenomegaly, elevated levels of Igs
(including autoantibodies), and the liver pathology that occur
spontaneously in ABIN1[D485N] mice (Figs. 3, 4, Supplemental
Fig. 4). These findings indicate that elevated levels of IFN-
regulated genes are not the primary cause of autoimmunity in
ABIN1[D485N] mice and that enhanced IFN signaling induces
the severity of glomerulonephritis by a mechanism that is inde-
pendent of autoantibody production. Our findings suggest that
SLE in patients expressing ABIN1 variants known to predispose
to this disease may derive relatively little benefit from anti–type
1 IFN therapy. However, it cannot be excluded that the overpro-
duction of type 2 and/or type 3 IFNs is also required to drive
autoimmunity.
In contrast to our findings, studies reported that crossing two
other lines of lupus-prone mice to IFNAR1-KO mice reduced the
levels of autoantibodies and glomerulonephritis and, therefore,
increased life span (38, 39). However, the mutations causing au-
toimmunity in these mice are unknown. Interestingly, in one of
these lines, blockade of IL-6 also suppressed the development of
autoimmunity (40, 41), indicating that elevated levels of more
than one cytokine are required to trigger SLE. The lupus nephritis
that develops in TANK-KO mice, and which is driven by hyper-
activation of the MyD88 signaling network (42, 43), was similarly
prevented by crossing to IL-6–KO mice (43). A recent study di-
vided human SLE into a number of categories: some display
elevated levels of IFN-regulated genes, whereas others have
elevated levels of different inflammatory cytokines and chemo-
kines (44). Taken together, these observations suggest that the
effective treatment of SLE patients will require the development
of a number of therapies, depending on the mutations that underlie
the disease.
The most striking finding in the current study was that the au-
toimmune phenotype of ABIN1[D485N] mice was prevented by
crossing to knock-in mice in which IRAK4 or IRAK1 was replaced
by catalytically inactive mutants. These results are consistent with
autoimmunity in ABIN1[D485N] mice being driven by hyper-
activation of the MyD88 signaling network and raise the possibility
that small molecule inhibitors of IRAK4 and/or IRAK1 prevent
(and perhaps reverse) autoimmune diseases in which alterations in
the TNIP1 gene encoding ABIN1 (Introduction) or other genes
causing hyperactivation of MyD88 signaling are a contributory
FIGURE 6. Glomerulonephritis in ABIN1[D485N]
mice is suppressed by crossing to mice expressing ki-
nase-inactive mutants of IRAK4 or IRAK1. Represen-
tative H&E staining (A) and PAS staining (B) of kidney
sections from 6-mo-old WT mice, ABIN1[D485N]–
knock-in mice, ABIN1[D485N] 3 IRAK4[D329A]
mice, ABIN1[D485N]3 IRAK1[D359A] mice, ABIN1
[D485N] 3 IRAK2[E525A] mice, IRAK4[D329A]
mice, IRAK1[D359A] mice, and IRAK2[E525A] mice.
Scale bars, 0.05 mm. (B) The arrowheads show PAS+
material. (C) Assessment of kidney pathology scores
(see Materials and Methods). All of the results shown
were carried out using four mice of each genotype.
*p . 0.05, Mann–Whitney U test. ns, not significant.
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factor. IRAK1 and IRAK4 do not participate in the cytoplasmic
pathways by which viral RNA (RIGI, MDA5 pathways) or DNA
(STING pathway) induce the production of type 1 IFNs (45, 46).
Therefore, SLE patients treated with IRAK1 or IRAK4 inhibitors
may have less risk for developing severe viral infection compared
with patients given anti-IFN therapy. IRAK4-deficient children are
susceptible to infection by pyogenic bacteria until they reach
puberty, but they are not more susceptible to viral infection (47).
Although genome-wide association studies identified IRAK1
polymorphisms as a risk factor for SLE (48–50), to our knowledge
the current study is the first to provide evidence that specific in-
hibition of IRAK1 kinase may have therapeutic potential for the
prevention of SLE. Such inhibitors might have significant
advantages compared with IRAK4-specific inhibitors or dual in-
hibitors of IRAK1 and IRAK4, which are likely to impair the
MyD88-dependent production of proinflammatory cytokines more
drastically than the loss of IRAK1 catalytic activity alone. For
example, the production of proinflammatory cytokines by several
TLR agonists was found to be unimpaired in BMDMs from
IRAK1[D359A] mice (28). In contrast, the production of type 1
IFNs and proinflammatory cytokines by ligands that activate the
MyD88 signaling network specifically was virtually abolished in
BMDMs from IRAK4[D329A]–knock-in mice (Supplemental Fig.
3), as well as in knock-in mice expressing different catalytically
inactive mutants of IRAK4 (36, 37). Therefore, patients treated
with an IRAK1-specific inhibitor might have a reduced risk for
infection by microbial pathogens than patients treated with an
IRAK4 inhibitor.
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